Share Name Share Symbol Market Type Share ISIN Share Description
International Biotechnology Trust Plc LSE:IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -8.00p -1.24% 638.00p 634.00p 638.00p 642.00p 634.00p 642.00p 50,945 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -2.5 -6.9 - 244

International Biotechnol... Share Discussion Threads

Showing 226 to 248 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
19/1/2013
22:21
http://www.ibtplc.com/assets/images/IBT%20Presentation%20AGM_05Dec12.pdf
davebowler
19/1/2013
22:17
http://www.ibtplc.com/fact_sheets/2012/December2012.pdf
davebowler
17/1/2013
13:46
BIOG is at a 1% premium http://www.trustnet.com/Factsheets/Factsheet.aspx?fundCode=AKFR0&univ=T whereas IBT (similar) is at a 16% discount.http://www.trustnet.com/Factsheets/Factsheet.aspx?fundCode=ITIBT&univ=T
davebowler
13/12/2012
16:52
Bought for SIPP; already hold BIOG & PCGH.
philo124
07/12/2012
14:17
http://www.edisoninvestmentresearch.co.uk/sectorreports/HealthcareQuarterly_Dec12.pdf
davebowler
26/11/2012
14:42
Ridiculously cheap at 17% discount to NAV compared to similar BIOG at 5% discount.
davebowler
23/11/2012
16:55
Why the recent decline in the s.p.? Profit taking?
gilston
19/10/2012
14:22
Good results today persuaded me to buy. A few key bits. "Investment Performance In this, my first letter to shareholders as Chairman, I am pleased to report to you a substantial positive return for the year ended 31 August 2012. The NAV increased by 41.9% to 232.5p per share. With a small narrowing of the discount to 12.0% from 12.7%, the Company's share price increased by 43.0%. By comparison, the FTSE All-Share Index produced a total return of just 10.2% over the same period. For the first time in several years, positive absolute performance was generated from both the quoted and unquoted parts of the portfolio, with a 47.8% and 21.7% increase for each, respectively. Investor enthusiasm for the biotechnology sector improved dramatically over the period against the backdrop of positive, yet muted, price gains for the broader stock market. With the Company's share price currently trading at a 12.0% discount to NAV, and the unquoted portfolio comprising 16.0% of overall NAV, the market is assigning little value to the unquoted portfolio. The Board believes this represents a valuation anomaly and offers investors an excellent opportunity to become Shareholders in the biotechnology industry's quiet revolution, even after the quoted sector's recent very strong run. The Company currently recognises GBP0.7m of fair value for future milestone payments potentially due to the Company from unquoted investments already exited. The receipt of these payments is contingent on pre-agreed, and legally-binding, operational or clinical development milestones being achieved. If paid in full, these milestone payments would amount to GBP9.6m on current exchange rates, representing GBP8.8m of additional unrecognised value."
127tolmers
27/9/2012
11:54
Bullish outlook; http://www.internationalbiotrust.com/press_releases/Biotech.pdf
davebowler
27/9/2012
11:53
I stand corrected -I only looked at the last 5 years!Presumably they peaked in the 'Tech' bubble.
davebowler
25/9/2012
15:12
Dave I wish this was all time high bought these about 10 years ago at around £3 I think they peaked just shy of £4 should have sold then. Holding since hoping they would come good one day. Only needs one good IPO and asset value will fly.
gallops
24/9/2012
16:35
All time high- Friday 21 Sep NAV Ex Income 243.95
davebowler
28/6/2012
13:23
All time high. http://www.fundweb.co.uk/investment-trusts/news/nick-train-we%E2%80%99re-at-the-start-of-massive-tech-bull-market/1053754.article
davebowler
01/6/2012
16:39
NAV Thursday 31 May Ex Income 221.32
davebowler
09/5/2012
15:55
NAV Tuesday 08 May Excluding Income 216.05
davebowler
27/4/2012
10:27
Portfolio Update The Board of International Biotechnology Trust plc (the "Company") notes that today a definitive agreement has been signed by Jazz Pharmaceuticals (NASDAQ:JAZZ) to buy the unquoted portfolio company EUSA Pharma for $650m in cash plus a potential $50m milestones payment. The Director's have changed the valuation of the Company's interest in EUSA Pharma by £1.9m from £2.7m to £4.6m on a cost of £2.4m to reflect the terms of the deal. This change in valuation will be included in the Company's Net Asset Value from today and will be released to the market on Monday. The increase to NAV per share in comparison to that released yesterday is 3.5 pence per share. Enquiries: Kate Bingham/David Pinniger Telephone: 020 7412 7070
davebowler
16/4/2012
11:47
Edison view; International Biotechnology Trust - Quoted portfolio continues to outperform PDF download Click for report International Biotechnology Trust's (IBT) quoted portfolio has, for the past three years, outperformed the NASDAQ Biotechnology Index. Although the unquoted portfolio (c 16%) has been a drag on overall performance, it is reaching maturity and may provide uplifts on exit, as reflected in the 2011 sale of Cadent to Align Technologies at 3.1x the carrying book value. The manager reports that exit conditions have improved significantly during the past six months, and currently expects five to six actions per year for the next two years, with further events in 2014/15. IBT aims to achieve long-term capital growth by investing in development stage biotechnology and other life sciences companies, both quoted and unquoted, that have high growth potential. IBT invests in companies considered to have good prospects, experienced management and strong upside potential through the development and/or commercialisation of a product, device or enablin g technology.
davebowler
09/2/2012
18:44
Steadily South.
sharejock
06/2/2012
15:51
Steadily North.
sharejock
06/12/2011
18:34
Tomorrow`s AGM should be interesting. The share buyback / cancellation process is very active.
gilston
06/12/2011
15:58
Amazing really - this is at an all time high.
davebowler
05/12/2011
16:45
Improving!
gilston
25/10/2011
13:25
Edison; International Biotechnology Trust - Improved fee structure PDF download Click for report With the recent results announcement, International Biotechnology Trust (IBT) confirmed a reduction in the annual management fee by 20bps to 1.15% of NAV with the aim of reducing the overall TER to below 2.0%. The quoted portfolio performance fee is also being adjusted, to 10% of any outperformance above the NASDAQ (sterling adjusted) Biotechnology Index plus 0.5%. The maximum total performance fee payable in a year falls from 5% of NAV to 3%. For now, the unquoted portfolio continues to act as a break on overall performance. However, IBT has recently successful exited Cadent with a sale to Align Technologies, at 3.1x book value. While recent market conditions have arguably delayed further exits the manager, SV Life Sciences, believes many of the unquoted names are reaching maturity and will provide strong exits, which will give a significant uplift to the unquoted performance. IBT aims to achieve long-term capital growth by investing in deve lopment stage biotechnology and other life sciences companies, both quoted and unquoted, that have high growth potential.
davebowler
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
IBT
Internatio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190722 22:26:09